Evolus Inc
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
EOLS$6.98+2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Financial Statements (unaudited)Condensed Consolidated Balance Sheets
PART I—FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
Condensed Consolidated Balance Sheets
(in thousands, except par value and share data)
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $67,894 | $86,952 |
| Accounts receivable, net | 47,454 | 47,682 |
| Inventories | 10,026 | 12,158 |
| Prepaid expenses | 3,452 | 3,349 |
| Other current assets | 2,892 | 1,201 |
| Total current assets | 131,718 | 151,342 |
| Property and equipment, net | 3,254 | 3,222 |
| Operating lease right-of-use assets | 6,922 | 7,185 |
| Intangible assets, net | 49,359 | 48,754 |
| Goodwill | 21,208 | 21,208 |
| Other assets | 900 | 858 |
| Total assets | $213,361 | $232,569 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities | ||
| Accounts payable | $16,176 | $9,236 |
| Accrued expenses | 26,619 | 40,791 |
| Operating lease liabilities | 1,967 | 1,718 |
| Contingent royalty obligation payable to Evolus Founders | 11,471 | 11,215 |
| Total current liabilities | 56,233 | 62,960 |
| Operating lease liabilities | 6,427 | 6,755 |
| Contingent royalty obligation payable to Evolus Founders | 33,080 | 33,550 |
| Term loan, net of discount and issuance costs | 121,807 | 121,506 |
| Contingent milestone payment | 2,416 | 2,270 |
| Deferred tax liability | 2 | 6 |
| Total liabilities | 219,965 | 227,047 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity (deficit) | ||
| Preferred stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | — | — |
| Common stock, $0.00001 par value; 100,000,000 shares authorized; 64,448,820 and 63,497,548 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 1 | 1 |
| Additional paid-in capital | 622,525 | 615,825 |
| Accumulated other comprehensive loss | (839) | (905) |
| Accumulated deficit | (628,291) | (609,399) |
| Total stockholders’ equity (deficit) | (6,604) | 5,522 |
| Total liabilities and stockholders’ equity (deficit) | $213,361 | $232,569 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.